Genetic testing to guide treatment for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that has spread to other parts of the body (metastatic).
- You have had at least one type of treatment for the metastatic cancer, or you can't take or don't want the standard treatments that might help.
- You have a biopsy sample from the last 6 months, or you can have a new biopsy (the study will test your tumor to find possible treatment options).
- You are 18 years or older and are generally able to do daily activities (with some help if needed).
- Your blood counts and organ function (like liver and kidneys) are within certain limits.
- You can take medications by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
This study tests if early genetic testing of your tumor can help find targeted treatments for advanced cancers that are hard to treat, such as pancreatic, liver, or triple-negative breast cancer. It aims to match you with a therapy based on your tumor's genetic profile.
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This trial studies how doing genetic (DNA) testing on your cancer helps doctors choose targeted treatments, and how those treatments affect outcomes. It is for adults whose cancer has not responded to the first standard treatment or who do not have curative options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.